Antitumor Activity of TLR7 Is Potentiated by CD200R Antibody Leading to Changes in the Tumor Microenvironment
Open Access
- 31 July 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 6 (8) , 930-940
Abstract
Stimulation of Toll-like receptor 7 (TLR7) activates myeloid cells and boosts the immune response. Previously, we have shown that stimulation of the inhibitory CD200 receptor (CD200R) suppresses TLR7 signaling and that the absence of CD200R signaling leads to a decreased number of papillomas in mice. Here, we investigated the effects of agonistic anti-CD200R on the antitumor activity of a TLR7 agonist (R848) in a syngeneic mouse tumor model. Intratumoral administration of R848 inhibited the growth of the CT26 colon carcinoma and simultaneously decreased CD200R expression in tumor-infiltrating immune cells. The antitumor effects of R848 were potentiated by anti-CD200R. Successfully treated mice were resistant to rechallenge with the same tumor cells. However, the immediate antitumor effects were independent of lymphocytes, because treatment efficacy was similar in wild-type and Rag1tm1Mom mice. Administration of R848, particularly in combination with anti-CD200R, changed the phenotype of intratumoral myeloid cells. The infiltration with immature MHC-II+ macrophages decreased and in parallel monocytes and immature MHC-II− macrophages increased. Combined treatment decreased the expression of the macrophage markers F4/80, CD206, CD86, CD115, and the ability to produce IL1β, suggesting a shift in the composition of intratumor myeloid cells. Adoptively transferred CD11b+ myeloid cells, isolated from the tumors of mice treated with R848 and anti-CD200R, inhibited tumor outgrowth in recipient mice. We conclude that administration of agonistic anti-CD200R improves the antitumor effects of TLR7 signaling and changes the local tumor microenvironment, which becomes less supportive of tumor progression. Cancer Immunol Res; 6(8); 1–11. ©2018 AACR.Keywords
Funding Information
- Polish Ministry of Science and Higher Education (0454/IP1/2013/72)
This publication has 26 references indexed in Scilit:
- Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signalingBreast Cancer Research and Treatment, 2013
- CD200 Receptor Controls Sex-Specific TLR7 Responses to Viral InfectionPLOS Pathogens, 2012
- CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing MiceClinical Cancer Research, 2011
- Programmed death ligand 2 regulates arginase induction and modifies Trypanosoma cruzi survival in macrophages during murine experimental infectionImmunology, 2011
- Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigmNature Immunology, 2010
- Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistanceJournal of Clinical Investigation, 2010
- Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in miceBreast Cancer Research and Treatment, 2009
- Type I Interferon Modulates Monocyte Recruitment and Maturation in Chronic InflammationThe American Journal of Pathology, 2009
- Expression of the Inhibitory CD200 Receptor Is Associated with Alternative Macrophage ActivationJournal of Innate Immunity, 2009
- Exploring the full spectrum of macrophage activationNature Reviews Immunology, 2008